Atreca (BCEL) Stock Price, News & Analysis

Company Overview

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Key Stats

• Today's Range: $0.09 to $0.09
• 50-Day Range: $0.09 to $0.09
• 52-Week Range: $0.05 to $1.20
• Volume: N/A
• Average Volume: 4.61 million shs
• Market Capitalization: $3.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BCEL Stock Analysis - Frequently Asked Questions

How were Atreca's earnings last quarter?

Atreca, Inc. (NASDAQ:BCEL) issued its earnings results on Tuesday, November, 2nd. The company reported ($0.74) EPS for the quarter, meeting analysts' consensus estimates of ($0.74).

When did Atreca IPO?

Atreca (BCEL) raised $126 million in an initial public offering on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.

What other stocks do shareholders of Atreca own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Atreca investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Micron Technology (MU), Alector (ALEC), Advanced Micro Devices (AMD), PayPal (PYPL) and Meta Platforms (META).

Company Calendar

• Last Earnings: 11/02/2021
• Today: 12/23/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCEL
• CUSIP: N/A
• CIK: 1532346
• Web: www.atreca.com
• Phone: (650) 595-2595
• Fax: N/A
• Employees: 130
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-97,160,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -157.90%
• Return on Assets: -71.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.58
• Quick Ratio: 1.58

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.01 per share
• Price / Book: 0.04

Miscellaneous

• Outstanding Shares: 39,624,000
• Free Float: 35,146,000
• Market Cap: $3.57 million
• Optionable: Optionable
• Beta: 1.03